Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis by Back, David et al.
J Viral Hepat. 2019;26:951–960.	 	 	 | 	951wileyonlinelibrary.com/journal/jvh
 
Received:	28	September	2018  |  Revised:	13	January	2019  |  Accepted:	11	February	2019
DOI:	10.1111/jvh.13110		
O R I G I N A L  A R T I C L E
Efficacy and safety of glecaprevir/pibrentasvir in patients with 
chronic HCV infection and psychiatric disorders: An integrated 
analysis
David Back1 |   Pamela Belperio2  |   Mark Bondin3 |   Francesco Negro4 |    
Andrew H. Talal5  |   Caroline Park3 |   ZhenZhen Zhang3 |   Brett Pinsky3 |   
Eric Crown3 |   Federico J. Mensa3 |   Fiona Marra1
1University	of	Liverpool,	Liverpool,	UK
2U.S.	Department	of	Veterans	Affairs,	VA	Palo	Alto	Healthcare	System,	Palo	Alto,	California
3AbbVie	Inc,	North	Chicago,	Illinois
4University	of	Geneva,	Geneva,	Switzerland
5Jacobs	School	of	Medicine	and	Biomedical	Sciences,	University	of	Buffalo,	Buffalo,	New	York
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided	the	original	work	is	properly	cited.
©	2019	The	Authors.	Journal of Viral Hepatitis	Published	by	John	Wiley	&	Sons	Ltd
Abbreviations:	AEs,	adverse	events;	ALT,	alanine	aminotransferase;	ATC,	Anatomical	Therapeutic	Chemical;	DAAs,	direct‐acting	antivirals;	DDIs,	drug–drug	interactions;	FSS,	Fatigue	
Severity	Scale;	HCV,	hepatitis	C	virus;	HIV,	human	immunodeficiency	virus;	IFN,	interferon;	ITT,	intent‐to‐treat;	MCS,	Mental	Component	Summary;	PROs,	patient‐reported	outcomes;	
QoL,	quality‐of‐life;	RT‐PCR,	reverse	transcriptase‐polymerase	chain	reaction;	SVR,	sustained	virologic	response;	TEAE,	treatment‐emergent	adverse	event.
Correspondence
David	Back,	Department	of	Molecular	
and	Clinical	Pharmacology,	Institute	of	
Translational	Medicine,	University	of	
Liverpool,	Liverpool,	UK.
Email:	d.j.back@liverpool.ac.uk
Funding information
AbbVie	sponsored	the	studies	
(NCT02243280,	NCT02243293,	
NCT02604017,	NCT02640482,	
NCT02640157,	NCT02636595,	
NCT02642432,	NCT02651194,	
NCT02446717	and	NCT02738138);	
contributed	to	their	design,	collection,	
analysis	and	interpretation	of	the	data;	
and	participated	in	the	writing,	review	and	
approval	of	this	manuscript.	All	authors	had	
access	to	relevant	data.	Glecaprevir	was	
identified	by	AbbVie	and	Enanta.	AbbVie	
is	committed	to	responsible	data	sharing	
regarding	the	clinical	trials	we	sponsor.	This	
includes	access	to	anonymized,	individual‐	
and	trial‐level	data	(analysis	data	sets),	and	
other	information	(eg,	protocols	and	Clinical	
Study	Reports),	as	long	as	the	trials	are	not	
part	of	an	ongoing	or	planned	regulatory	
submission.	This	includes	requests	for	
clinical	trial	data	for	unlicensed	products	and	
indications.	These	clinical	trial	data	can	be	
requested	by	any	qualified	researchers	who	
Abstract
Although	direct‐acting	antivirals	(DAAs)	for	chronic	hepatitis	C	virus	(HCV)	infection	
are	highly	efficacious	and	safe,	treatment	initiation	is	often	limited	in	patients	with	
neuropsychiatric	disorders	due	to	concerns	over	reduced	treatment	adherence	and	
drug–drug	interactions.	Here,	we	report	adherence,	efficacy,	safety	and	patient‐re‐
ported	outcomes	 (PROs)	 from	an	 integrated	analysis	of	 registrational	studies	using	
the	pangenotypic	DAA	regimen	of	glecaprevir	and	pibrentasvir	(G/P).	Patients	with	
chronic	HCV	genotypes	1‐6	infection	with	compensated	liver	disease	(with	or	without	
cirrhosis)	receiving	G/P	for	8,	12	or	16	weeks	were	included	in	this	analysis.	Patients	
were	classified	as	having	a	psychiatric	disorder	based	on	medical	history	and/or	co‐
medications.	Primary	analyses	assessed	treatment	adherence,	efficacy	(sustained	vi‐
rologic	response	at	post‐treatment	week	12;	SVR12),	safety	and	PROs.	Among	2522	
patients	receiving	G/P,	789	(31%)	had	a	psychiatric	disorder	with	the	most	common	
diagnoses	being	depression	 (64%;	506/789)	and	anxiety	disorders	 (27%;	216/789).	
Treatment	adherence	was	comparably	high	(>95%)	in	patients	with	and	without	psy‐
chiatric	disorders.	SVR12	rates	were	97.3%	(768/789;	95%	CI	=	96.2‐98.5)	and	97.5%	
(1689/1733;	95%	CI	=	96.7‐98.2)	in	patients	with	and	without	psychiatric	disorders,	
respectively.	Among	patients	with	psychiatric	disorders,	SVR12	rates	remained	>96%	
by	individual	psychiatric	diagnoses	and	co‐medication	classes.	Overall,	most	adverse	
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1  | INTRODUC TION
Chronic	hepatitis	C	virus	infection	is	associated	with	neuropsychiatric	
disorders	in	up	to	50%	of	cases.1,2	Historically,	patients	with	comor‐
bid	psychiatric	disorders	were	less	 likely	to	receive	HCV	treatment	
since	 interferon	 (IFN)‐based	 regimens	 can	 induce	 depression	 and	
other	neuropsychiatric	manifestations	including	insomnia,	irritability	
and	mood	changes.3	Treatment	adherence	among	this	patient	popu‐
lation	was	also	a	concern	due	to	IFN's	psychiatric	side	effect	profile	
and	perceived	risks	of	lower	adherence	in	patients	with	psychiatric	
and/or	 substance	use	disorders.3	Yet,	 fatigue	and	psychological	 is‐
sues	contribute	significantly	 to	quality‐of‐life	 (QoL)	 impairments	 in	
patients	with	chronic	HCV	infection,	both	of	which	can	be	improved	
by	the	achievement	of	sustained	virologic	response	(SVR).4,5
The	introduction	of	direct‐acting	antivirals	(DAAs)	provided	IFN‐
free	 treatment	 regimens	 that	 likely	 are	more	 suitable	 for	 patients	
with	 chronic	 HCV	 infection	 and	 comorbid	 psychiatric	 disorders.	
Both	clinical	trials	and	real‐world	evidence	have	demonstrated	that	
these	all‐oral,	IFN‐free	regimens	are	highly	efficacious	and	well	tol‐
erated	with	minimal	 treatment‐emergent	 neuropsychiatric	 side	 ef‐
fects	in	patients	with	chronic	HCV	infection.6‐8	Based	on	these	data,	
recent	HCV	treatment	guidelines	recommend	DAA	regimens	with‐
out	any	restrictions	based	on	psychiatric	comorbidities.9,10	However,	
there	has	been	more	limited	use	of	DAAs	in	patients	with	psychiatric	
disorders	in	both	late	phase	trials	and	clinical	practice	potentially	due	
to	concerns	about	treatment	adherence	and	drug–drug	interactions	
(DDIs)	with	neuropsychiatric	co‐medications.3,11‐14	Thus,	there	is	an	
unmet	need	to	better	understand	the	impact	of	psychiatric	disorders	
on	the	treatment	adherence,	efficacy	and	safety	of	DAA	regimens.
Glecaprevir	 (GLE;	 NS3/4A	 protease	 inhibitor	 identified	 by	
AbbVie	and	Enanta)	and	pibrentasvir	(PIB;	NS5A	inhibitor)	are	potent	
pangenotypic	inhibitors	co‐formulated	as	G/P,	an	all‐oral,	once‐daily	
and	 pangenotypic	 DAA	 regimen	 that	 demonstrated	 high	 efficacy,	
and	favourable	safety	and	DDI	profiles	in	patients	with	chronic	HCV	
infection.	In	vitro,	glecaprevir	and	pibrentasvir	exhibited	nanomolar	
and	picomolar	potencies,	respectively,	against	all	major	HCV	geno‐
types	and	both	retained	their	activity	against	most	resistance‐asso‐
ciated	substitutions.15,16	Phase	1	trials	investigated	and	thoroughly	
characterized	the	DDI	profile	of	G/P,	finding	limited	interactions	and	
demonstrating	that	the	majority	of	concomitant	medications,	includ‐
ing	neuropsychiatric	medications,	can	be	safely	taken	with	G/P	with‐
out	dose	modification.17,18	In	late	phase	clinical	trials,	G/P	was	highly	
efficacious	and	safe	in	patients	with	chronic	HCV	genotypes	1‐6	in‐
fection	including	in	patients	with	compensated	cirrhosis,	end‐stage	
renal	disease	and	co‐infection	with	human	immunodeficiency	virus	
(HIV).19‐26	 Preliminary	 reports	 from	 real‐world	 cohorts	 have	 sup‐
ported	 these	clinical	 trial	 findings	with	G/P	showing	similarly	high	
effectiveness	and	a	favourable	safety	profile	in	clinical	practice.27,28
Here,	we	present	an	integrated	analysis	of	ten	Phase	2	and	Phase	
3	studies	aimed	at	evaluating	the	impact	of	psychiatric	disorders	on	
the	treatment	adherence,	efficacy,	safety	and	patient‐reported	out‐
comes	(PROs)	with	G/P	treatment.
2  | METHODS
2.1 | Analysis set
Data	were	pooled	from	2,522	patients	with	chronic	HCV	genotype	1‐6	
infection	 and	 either	 without	 cirrhosis	 or	 with	 compensated	 cirrhosis	
who	received	G/P	in	ten	Phase	2	and	Phase	3	clinical	trials	that	assessed	
efficacy,	 safety,	 treatment	 adherence	 and	 PROs	 (SURVEYOR‐I	 and	
SURVEYOR‐II	and	MAGELLAN‐1,	and	ENDURANCE‐1,	ENDURANCE‐2,	
ENDURANCE‐3	 and	 ENDURANCE‐4,	 and	 EXPEDITION‐1,	
EXPEDITION‐2	 and	 EXPEDITION‐4).19‐26	 This	 integrated	 analysis	
set	included	all	patients	who	received	at	least	one	dose	of	glecaprevir	
300	mg	and	pibrentasvir	120	mg	either	as	separate	tablets	(Phase	2	for‐
mulation)	or	co‐formulated	tablets	dosed	orally	as	three	pills	for	a	total	
300mg/120mg	 dose	 (Phase	 3	 formulation).	 Both	 formulations	 were	
given	as	once‐daily,	all‐oral	regimens	for	8,	12	or	16	weeks.	All	authors	
had	access	to	data,	and	reviewed	and	approved	the	final	manuscript.
2.2 | Patients
Complete	inclusion	and	exclusion	criteria	were	similar	across	all	clini‐
cal	trials	minus	key	trial‐specific	eligibility	criteria	noted	in	Table	S1.	
Adults	(≥18	years	of	age)	with	chronic	HCV	genotype	1‐6	infection	
were	eligible	for	the	studies	if	they	were	positive	for	anti‐HCV	anti‐
body	with	a	plasma	HCV	RNA	viral	load	≥10	000	IU/mL	in	Phase	2	
engage	in	rigorous,	independent	scientific	
research,	and	will	be	provided	following	
review	and	approval	of	a	research	proposal	
and	Statistical	Analysis	Plan	(SAP)	and	
execution	of	a	Data	Sharing	Agreement	
(DSA).	Data	requests	can	be	submitted	at	
any	time	and	the	data	will	be	accessible	
for	12	months,	with	possible	extensions	
considered.	For	more	information	on	the	
process,	or	to	submit	a	request,	visit	the	
following	link:	https	://www.abbvie.com/
our‐scien	ce/clini	cal‐trial	s/clini	cal‐trials‐
data‐and‐infor	mation‐shari	ng/data‐and‐
infor	mation‐shari	ng‐with‐quali	fied‐resea	
rchers.html.
events	(AEs)	were	mild‐to‐moderate	in	severity	with	serious	AEs	and	AEs	leading	to	
G/P	discontinuation	occurring	at	 similarly	 low	rates	 in	both	patient	populations.	 In	
conclusion,	G/P	treatment	was	highly	efficacious,	well‐tolerated	and	demonstrated	
high	adherence	rates	in	patients	with	chronic	HCV	infection	and	psychiatric	disorders.
K E Y W O R D S
chronic	hepatitis	C,	drug	interactions,	mental	disorders,	sustained	virologic	response,	
treatment adherence and compliance
     |  953BACK et Al.
trials	or	≥1000	IU/mL	in	Phase	3	trials	at	the	screening	visit.	Patients	
were	eligible	if	they	were	either	HCV	treatment‐naïve	or	had	prior	
treatment	experience	with	IFN/pegylated	(peg)	IFN	±	ribavirin	(RBV)	
or	 sofosbuvir	 +	RBV	±	pegIFN.	Medical	 history	 of	 psychiatric	 dis‐
orders	was	 not	 exclusionary	 unless	 it	was	 uncontrolled	 and	made	
the	subject	an	unsuitable	candidate	for	the	trial	as	assessed	by	the	
study	investigator.	Ongoing	drug	or	alcohol	use	was	not	exclusionary	
unless	it	could	preclude	adherence	as	assessed	by	the	study	inves‐
tigator.	Other	medical	diagnoses	were	not	exclusionary	unless	they	
were	uncontrolled,	including,	but	not	limited	to,	cardiac,	respiratory,	
gastrointestinal,	haematologic,	neurologic,	or	other	medical	diseases	
or	 disorders	 not	 related	 to	 existing	 HCV	 infection.	 Patients	 were	
excluded	 if	 they	had	active	or	 suspected	malignancy	or	history	of	
malignancy	in	the	past	5	years	except	basal	cell	skin	cancer	or	cervi‐
cal	carcinoma	in	situ.	Patients	were	also	excluded	if	they	required	or	
could	not	safely	discontinue	the	following	medications:	any	herbal	
supplement,	red	yeast	rice	(monacolin	K),	St.	John's	Wort,	carbamaz‐
epine,	phenytoin,	pentobarbital,	phenobarbital,	primidone,	rifabutin,	
rifampin,	atorvastatin,	 lovastatin,	simvastatin,	astemizole,	cisapride	
and	 terfenadine.	 All	 patients	 provided	 written	 informed	 consent.	
Clinical	trials	were	designed	and	conducted	in	accordance	with	the	
Good	Clinical	Practice	guidelines,	Declaration	of	Helsinki,	 and	ap‐
plicable	local	regulation	and	with	approval	from	independent	ethics	
committees	or	institutional	review	boards	at	all	study	sites.
In	 this	 post	 hoc	 analysis,	 patients	 receiving	 at	 least	 one	 dose	
of	G/P	were	 classified	as	having	a	psychiatric	disorder	by	medical	
history	 and/or	 concomitant	 medication	 use.	 Medical	 history	 was	
used	to	classify	patients	as	having	a	psychiatric	disorder	if	they	had	
been	 previously	 diagnosed	 with	 any	 of	 the	 following	 psychiatric	
or	 neurological	 disorders	 including	 anxiety,	 bipolar	 disorder,	 cog‐
nitive	 or	 psychiatric	 disorder,	 depression,	 Parkinson's	 disease,	 and	
seizure	 disorder	 or	 convulsions.	 Concomitant	medication	 use	was	
used	to	classify	patients	as	having	a	psychiatric	disorder	if	patients	
were	receiving	antidepressants	or	antipsychotics	as	defined	by	the	
Anatomical	Therapeutic	Chemical	(ATC)	Classification	System.
2.3 | Procedures
Real‐time	 reverse	 transcriptase‐polymerase	 chain	 reaction	 (RT‐
PCR)	was	 utilized	 to	 quantify	 plasma	HCV	RNA	 for	 both	 baseline	
viral	 load	 and	 SVR12	 assessments;	 assay	 details	 are	 described	 in	
the	Supporting	 Information.	HCV	genotype	was	determined	using	
the	 Versant®	 HCV	 Genotype	 Inno	 LiPA	 Assay,	 Version	 2.0	 or	
higher	 (LiPA;	Siemens	Healthcare	Diagnostics,	Tarrytown,	NY)	and	
confirmed	 by	 phylogenetic	 analysis	 of	 viral	 sequences.	 Treatment	
adherence	 was	 assessed	 using	 pill	 count	 at	 visits	 every	 4	 weeks	
during	the	treatment	period	including	at	the	end	of	treatment	visit.	
Adherence	was	defined	as	the	lowest	adherence	to	G/P	being	≥80%	
and	≤120%	at	all	intervals	between	baseline	and	end	of	treatment.	
Post	hoc	analysis	imputed	any	missing	values	for	drug	adherence	at	
any	of	 the	 treatment	visits	 as	 the	 lowest	obtained	value	 from	 the	
patient's	other	visits.	An	exploratory	analysis	assessed	PROs	related	
to	neuropsychiatric	function	for	patients	with	or	without	psychiatric	
disorders	by	evaluating	the	mean	change	from	baseline	to	post‐treat‐
ment	 week	 12	 on	 the	 Short‐Form	 36	 (SF‐36)	Mental	 Component	
Summary	(MCS)	and	Fatigue	Severity	Scale	(FSS).
Safety	was	evaluated	by	monitoring	adverse	events	 (AEs),	vital	
signs,	 physical	 examination	 findings,	 electrocardiography	 and	 clin‐
ical	 laboratory	 tests.	Nonserious	 and	 serious	AEs	were	monitored	
throughout	G/P	treatment	until	30	days	post‐treatment	and	up	 to	
24	weeks	post‐treatment,	respectively.	Any	AE	with	an	onset	date	
after	the	first	G/P	dose	and	no	more	than	30	days	after	the	last	G/P	
dose	was	classified	as	a	treatment‐emergent	adverse	event	(TEAE).	
All	 AEs	 were	 coded	 using	 the	 Medical	 Dictionary	 for	 Regulatory	
Activities	 (MedDRA)	and	were	assessed	for	 their	 relationship	with	
G/P	by	study	investigators.
2.4 | Endpoints
The	primary	endpoints	of	this	integrated	analysis	were	the	efficacy	
and	safety	of	G/P	in	patients	with	chronic	HCV	genotype	1‐6	infec‐
tion	with	or	without	 a	 psychiatric	 disorder.	 Efficacy	was	 evaluated	
by	SVR	(HCV	RNA	<	lower	limit	of	quantification)	at	12	weeks	post‐
treatment	in	the	intent‐to‐treat	(ITT)	population	for	patients	with	or	
without	a	psychiatric	disorder.	Safety	was	evaluated	by	characterizing	
reported	AEs	and	the	number	and	percentage	of	G/P‐treated	patients	
who	 reported	 treatment‐emergent	 adverse	 events	 and	 laboratory	
abnormalities,	both	in	total	and	stratified	by	the	presence	or	absence	
of	a	psychiatric	disorder.	Additional	endpoints	 included	analyses	of	
treatment	 adherence,	 patient‐reported	 health	 outcomes	 related	 to	
neurocognitive	function	and	subgroup	analyses	of	SVR12	in	patients	
by	neuropsychiatric	co‐medications	or	psychiatric	diagnoses.
2.5 | Statistical analysis
The	number	and	percentage	of	patients	in	the	ITT	population	achiev‐
ing	SVR12	for	patients	with	or	without	psychiatric	disorders	were	sum‐
marized	with	two‐sided	95%	confidence	intervals	calculated	using	the	
normal	approximation	 to	 the	binomial	distribution.	Further	analyses	
evaluated	SVR12	rates	by	ITT	analysis	in	subgroups	of	patients	with	
psychiatric	disorders	in	order	to	assess	whether	common	psychiatric	
disorders	and/or	co‐medications	affected	achievement	of	SVR12.
3  | RESULTS
3.1 | Baseline patient demographics and 
characteristics
This	 analysis	 of	Phase	2	 and	Phase	3	 clinical	 trial	 data	 consisted	of	
2522	 patients	 with	 chronic	 HCV	 genotypes	 1‐6	 infection	 treated	
with	G/P	for	either	8,	12	or	16	weeks	following	enrolment	between	7	
October	2014	and	12	September	2016.	Overall,	this	clinical	trial	popu‐
lation	included	789	(31%)	patients	classified	as	having	a	psychiatric	dis‐
order	based	on	a	previous	medical	history	of	≥1	psychiatric	disorder	
(90%;	708/789)	and/or	concomitant	psychiatric	medication	use	(58%;	
455/789).	Table	1	delineates	the	baseline	and	disease	characteristics	
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of	patients	with	or	without	a	psychiatric	disorder.	Patients	with	psy‐
chiatric	disorders	were	more	often	female	(49%	vs	40%,	respectively),	
white	 (87%	 vs	 77%,	 respectively),	 GT3‐infected	 (32%	 vs	 24%,	 re‐
spectively)	 and	had	higher	prevalence	of	 cirrhosis	 (16%	vs	11%,	 re‐
spectively)	 and	medical	 history	 of	 injection	 drug	 use	 (56%	 vs	 34%,	
respectively)	compared	to	those	without	a	psychiatric	disorder.
The	most	 common	concomitant	medication	 for	 each	of	 these	
neuropsychiatric	drug	classes	is	listed	in	Table	2	for	patients	with	or	
without	psychiatric	disorders	when	appropriate.	Among	the	most	
common	 neuropsychiatric	 medications	 used	 concomitantly	 with	
G/P,	the	University	of	Liverpool	website	only	identified	quetiapine	
(N	=	47),	hydrocodone	(N	=	77)	and	oxycodone	(N	=	81)	as	neuro‐
psychiatric	co‐medications	with	potential	DDIs	with	G/P	(Table	2).
3.2 | Treatment adherence
Treatment	adherence	was	similarly	high	among	patients	with	or	without	
a	psychiatric	disorder	(95.4%	and	96.7%,	respectively;	Table	1).	Table	3	
illustrates	high	(>94%)	treatment	adherence	rates	among	patients	with	
histories	of	depression	or	anxiety	disorders;	treatment	adherence	was	
lowest	in	patients	with	a	history	of	bipolar	disorder	(89.5%).	Treatment	
adherence	remained	high	(>94%)	for	those	prescribed	neuropsychiatric	
co‐medication	classes	(Table	3)	and	for	patients	taking	>1	psychiatric	
co‐medication	or	16‐week	G/P	treatment	(Table	S2).
TA B L E  1  Baseline	demographics	and	disease	characteristics	for	
patients	with	or	without	a	psychiatric	disorder
Characteristic
Patients with psy-
chiatric disorders 
N = 789
Patients without 
a psychiatric 
disorder 
N = 1733
Male,	n	(%) 403	(51) 1043	(60)
Age,	median	(range),	
years
53	(21‐82) 54	(19‐88)
Race,	n	(%)
White 685	(87) 1,334	(77)
Black	or	
African‐American
53	(7) 121	(7)
Asian 36	(5) 242	(14)
Other 13	(2) 35	(2)
Missing 2 1
BMI,	median	(range),	
kg/m2
26.4	(17.3‐55.4) 25.6	(17.4‐65.7)
Baseline	HCV	RNA	
level,	median	(range),	
log10	IU/mL
6.3	(1.2‐7.6) 6.2	(0.7‐7.8)
HCV	genotype,	n	(%)
GT1 331	(42) 764	(44)
GT2 144	(18) 332	(19)
GT3 251	(32) 418	(24)
GT4‐6 63	(8) 219	(13)
HCV	treatment‐naïve,	
n	(%)
568	(72) 1,197	(69)
HCV	treatment‐experi‐
enced,	n	(%)
221	(28) 536	(31)
IFN‐experienced 180	(23) 464	(27)
PI/NS5A‐experienced 41	(5) 72	(4)
Fibrosis	status,	n	(%)
F0‐F1 541	(69) 1,230	(71)
F2 41	(5) 126	(7)
F3 83	(11) 177	(10)
F4 123	(16) 196	(11)
Missing 1 4
G/P	treatment	duration,	n	(%)
8	wk 312	(40) 653	(38)
12	wk 433	(55) 1004	(58)
16	wk 44	(6) 76	(4)
History	of	injection	
drug	usea
439	(56) 595	(34)
History	of	psychiatric	disorders	≥5%	of	patients,	n	(%)
Depression 506	(64) N/Ab
Anxiety 216	(27) N/Ab
Cognitive	or	psychi‐
atric	Disorder
97	(12) N/Ab
Bipolar	disorder 57	(7) N/Ab
(Continues)
Characteristic
Patients with psy-
chiatric disorders 
N = 789
Patients without 
a psychiatric 
disorder 
N = 1733
Concomitant	neuropsychiatric	drug	use	in	≥10%	of	patients	by	class,	
n	(%)c
Antidepressants 396	(50) N/Ab
Opioids 272	(34) 221	(13)
Anxiolytics 244	(31) 74	(4)
Antiepileptic 217	(28) 69	(4)
Hypnotics	and	
sedatives
159	(20) 98	(6)
Antipsychotics 117	(15) N/Ab
Drugs	used	for	
substance	use	
disordersd
116	(15) 98	(6)
Treatment	adherent,	
n	(%)
753	(95) 1676	(97)
Abbreviations:	BMI,	body	mass	index;	HCV,	hepatitis	C	virus;	GT,	geno‐
type;	IFN,	interferon;	PI,	protease	inhibitor;	N/A,	not	applicable.
aIncludes	all	patients	who	previously	injected	drugs	regardless	of	how	
recent	the	patient‐injected	drugs.	
bNot	applicable	to	patients	without	psychiatric	disorders	since	this	
parameter	was	used	to	define	the	population	with	psychiatric	disorders.	
cConcomitant	medications	grouped	by	Anatomical	Therapeutic	
Chemical	(ATC)	Classification	System.	
dIncludes	the	following	drugs:	methadone,	buprenorphine	(with	or	
without	naloxone),	nicotine,	diamorphine,	levomethadone,	disulfiram,	
naltrexone,	varenicline,	acamprosate	and	naloxone.	
TA B L E  1   (Continued)
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3.3 | Efficacy outcomes
SVR12	 rates	 for	 the	 ITT	 population	 were	 97.3%	 (768/789;	 95%	
CI	=	96.2‐98.5)	in	patients	with	a	psychiatric	disorder	compared	to	
97.5%	(1689/1733;	95%	CI	=	96.7‐98.2)	in	those	without	a	psychiat‐
ric	disorder	(Figure	1).	The	rate	of	virologic	failure	was	1.0%	(8/789)	
among	 patients	 with	 a	 psychiatric	 disorder	 compared	 to	 1.5%	
(26/1733)	 in	 patients	 without	 a	 psychiatric	 disorder.	 Nonvirologic	
TA B L E  2  Most	common	neuropsychiatric	co‐medications	by	anatomical	therapeutic	chemical	(ATC)	class
Drug class Medication
Patients with Psychiatric 
Disorders N = 789 (n, %)
Patients without a Psychiatric 
Disorder 
N = 1733 (n, %)
Overall 
N = 2522 (n, %)
Antidepressantsa Trazodone 62	(7.9) 0 62	(2.5)
Escitalopram 57	(7.3) 0 57	(2.3)
Citalopram 48	(6.1) 0 48	(1.9)
Bupropion 45	(5.7) 0 45	(1.8)
Sertraline 45	(5.7) 0 45	(1.8)
Opioids Codeineb 49	(6.2) 46	(2.7) 95	(3.8)
Tramadol 45	(5.7) 36	(2.1) 81	(3.2)
Oxycodoneb,c 52	(6.6) 29	(1.7) 81	(3.2)
Hydrocodoneb,c 50	(6.3) 27	(1.6) 77	(3.1)
Morphine 17	(2.2) 12	(0.7) 29	(1.1)
Anxiolytics Alprazolam 65	(8.2) 21	(1.2) 86	(3.4)
Clonazepam 44	(5.6) 8	(0.5) 52	(2.1)
Diazepam 42	(5.3) 10	(0.6) 52	(2.1)
Lorazepam 40	(5.1) 9	(0.5) 49	(1.9)
Hydroxyzine 15	(1.9) 14	(0.8) 29	(1.1)
Antiepileptic Gabapentin 68	(8.6) 31	(1.8) 99	(3.9)
Pregabalin 21	(2.7) 8	(0.5) 29	(1.1)
Lamotrigine 18	(2.3) 1	(<0.1) 19	(0.8)
Levetiracetam 15	(1.9) 2	(0.1) 17	(0.7)
Valproic	Acid 7	(0.9) 2	(0.1) 9	(0.4)
Hypnotics	and	sedatives Zolpidem 43	(5.4) 24	(1.4) 67	(2.4)
Diphenhydramine 27	(3.4) 17	(1) 44	(1.7)
Zopiclone 20	(2.5) 20	(1.2) 40	(1.6)
Melatonin 20	(2.5) 9	(0.5) 29	(1.1)
Promethazine 17	(2.2) 5	(0.3) 22	(0.9)
Antipsychoticsa Quetiapinec 47	(6) 0 47	(1.9)
Risperidone 18	(2.3) 0 18	(0.7)
Lithium 11	(1.4) 0 11	(0.4)
Olanzapine 11	(1.4) 0 11	(0.4)
Aripiprazole 9	(1.1) 0 9	(0.4)
Drugs	used	in	substance	use	disorders Methadone 60	(7.6) 60	(3.5) 120	(4.8)
Buprenorphine	
with	naloxone
19	(2.4) 13	(0.8) 32	(1.3)
Buprenorphine 18	(2.3) 8	(0.5) 26	(1.0)
Nicotine 10	(1.3) 14	(0.8) 24	(1.0)
Diamorphine 3	(0.4) 2	(0.1) 5	(0.2)
Note:	Anatomical	Therapeutic	Chemical.
aNot	applicable	to	patients	without	psychiatric	disorders	since	patients	taking	these	co‐medications	were	defined	as	having	a	psychiatric	disorder.	
bIncludes	patients	taking	a	regimen	containing	the	listed	generic	drug	name.	
cMedications	with	potential	interactions	with	G/P	based	on	the	University	of	Liverpool	website	(www.hep‐drugi	ntera	ctions.org).	
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failures	from	premature	discontinuations	of	G/P	and	lost	to	follow‐
up	each	occurred	in	less	than	1%	of	patients	regardless	of	the	pres‐
ence	or	absence	of	a	psychiatric	disorder.
Subgroup	analyses	 in	the	ITT	population	demonstrated	numer‐
ically	comparable	SVR12	rates	 in	patients	with	and	without	a	psy‐
chiatric	disorder	regardless	of	patient	characteristics	including	age,	
fibrosis	stage,	treatment	duration	and	treatment	adherence	(Figures	
S1	and	S2).	Although	SVR12	rates	by	ITT	analysis	were	numerically	
lower	in	all	patients	who	were	nonadherent	than	in	those	who	were	
adherent,	exclusion	of	nonvirologic	 failures	 (early	discontinuations	
or	 lost	 to	 follow‐up)	 using	 a	 modified	 ITT	 analysis	 demonstrated	
numerically	similar	SVR12	rates	regardless	of	treatment	adherence	
(Figure	S2).	SVR12	rates	(%,	n/N)	remained	high	in	all	patients	taking	
a	neuropsychiatric	co‐medication	with	a	potential	DDI,	namely	que‐
tiapine	(100%,	47/47),	oxycodone	(93.8%,	76/81)	and	hydrocodone	
(97.4%,	75/77)	(Figure	S3).
SVR12	rates	by	ITT	analysis	were	further	stratified	for	patients	
with	 psychiatric	 disorders	 by	 common	 psychiatric	 diagnoses	 and	
neuropsychiatric	 co‐medication	 classes	 (Figure	 2).	 SVR12	 rates	
were	 >97%	 for	 patients	with	 the	most	 common	 psychiatric	 disor‐
ders,	namely	depression	(97.2%;	95%	CI	=	95.8‐98.7),	anxiety	disor‐
ders	(98.1%;	95%	CI	=	96.4‐99.9)	and	bipolar	disorder	(98.2%;	95%	
CI	=	94.8‐100).	Similarly,	SVR12	rates	were	>97%	for	all	of	the	most	
common	neuropsychiatric	co‐medication	classes	 (Figure	2)	and	re‐
mained	high	(>96%)	for	patients	with	psychiatric	disorders	not	taking	
a	concomitant	psychiatric	medication	(Figure	S4).
3.4 | Safety outcomes
Among	the	1697	(67%)	patients	experiencing	an	AE,	610	(77%)	pa‐
tients	with	a	psychiatric	disorder	reported	an	AE	compared	to	1087	
(63%)	 patients	without	 a	 psychiatric	 disorder	 (Table	 4).	Most	 AEs	
were	classified	as	either	mild	(Grade	1)	or	moderate	(Grade	2)	in	se‐
verity	for	patients	with	(568/610;	93%)	and	without	a	psychiatric	dis‐
order	(1035/1087;	95%).	Overall,	the	most	common	AEs	occurring	in	
≥10%	of	patients	with	or	without	a	psychiatric	disorder,	respectively,	
were	headache	(20%	vs	16%),	fatigue	(18%	vs	13%)	and	nausea	(13%	
vs	8%),	and	these	tended	to	occur	more	often	in	patients	with	a	psy‐
chiatric	disorder.	Neuropsychiatric	AEs	were	not	observed	in	≥10%	
of	patients	for	either	population,	but	tended	to	occur	more	often	in	
patients	with	a	psychiatric	disorder	than	those	without	a	psychiatric	
disorder	(8%	vs	3%,	respectively).
Adverse	events	leading	to	G/P	discontinuation	and	G/P‐related	
serious	 AEs	 were	 rare	 (<1%)	 in	 both	 patients	 with	 and	 without	 a	
psychiatric	 disorder	 (Table	 4).	 Serious	AEs	occurred	 at	 similar	 fre‐
quencies	in	patients	with	and	without	psychiatric	disorders.	No	pa‐
tients	with	psychiatric	disorders	experienced	a	G/P‐related	serious	
AE	as	assessed	by	 the	 study	 investigator.	G/P‐related	AEs	 leading	
to	discontinuation	were	reported	in	5	(<1%)	patients,	including	two	
TA B L E  3  Treatment	adherence	in	patients	with	psychiatric	
disorder	by	diagnosis	and	neuropsychiatric	co‐medication
Characteristic, % (n/N)
G/P treatment 
adherence
History	of	Psychiatric	Disordera
Depression 95.7	(484/506)
Anxiety 95.4	(206/216)
Bipolar	disorder 89.5	(51/57)
Concomitant	Neuropsychiatric	drug	use
Antidepressants 95.2	(377/396)
Opioids 94.9	(258/272)
Anxiolytics 95.1	(232/244)
Antiepileptics 94.5	(205/217)
Hypnotics	and	sedatives 96.2	(153/159)
Antipsychotics 94.9	(111/117)
Drugs	used	in	substance	use	disorders 96.6	(112/116)
Abbreviation:	G/P,	glecaprevir/pibrentasvir.
aReported	in	previous	patient	medical	history.	
F I G U R E  1  SVR12	by	ITT	analysis	for	patients	with	and	without	
a	psychiatric	disorder.	G/P	efficacy,	defined	as	SVR12,	is	reported	
both	overall	and	by	presence	or	absence	of	psychiatric	disorders.	
Reasons	for	nonresponse	are	reported	for	virologic	(breakthrough	
or	relapse)	and	nonvirologic	(discontinuation	or	lost	to	follow‐up)	
failure
F I G U R E  2  SVR12	by	ITT	analysis	stratified	by	psychiatric	
diagnosis	or	neuropsychiatric	co‐medication	for	patients	with	
psychiatric	disorders.	SVR12	data	in	patients	with	psychiatric	
disorders	further	stratified	by	individual	psychiatric	disorders	(light	
blue)	or	neuropsychiatric	co‐medications	(blue)
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patients	with	psychiatric	disorders	who	discontinued	due	to	nonse‐
rious	AEs	of	dyspepsia	on	Day	70	and	adverse	events	 (nausea,	di‐
arrhoea,	dizziness,	 fatigue,	malaise,	 abdominal	pain	and	headache)	
at	 Day	 5,	 respectively.	 Similar	 rates	 of	 AEs	 and	 G/P‐related	 AEs	
leading	to	discontinuation	were	observed	in	patients	taking	a	neuro‐
psychiatric	co‐medication	with	a	potential	DDI,	namely	quetiapine,	
oxycodone	and	hydrocodone	(Table	S3).	Although	serious	AEs	were	
reported	at	numerically	higher	rates	for	patients	taking	oxycodone	
(11%)	or	hydrocodone	(6%),	none	of	the	serious	AEs	were	due	to	re‐
spiratory	depression	or	related	to	G/P	(Table	S3).
Laboratory	abnormalities	were	also	 rare	 (<1%)	 in	patients	with	
and	without	a	psychiatric	disorder	 (Table	4).	Grade	3	elevations	 in	
alanine	aminotransferase	(ALT)	were	rare	(<1%)	in	both	populations,	
with	1	 (<1%)	patient	with	a	psychiatric	disorder	exhibiting	a	single	
Grade	3	ALT	elevation	at	Day	7	from	a	previous	Grade	2	ALT	eleva‐
tion.	The	Grade	3	ALT	elevation	in	the	patient	without	a	psychiatric	
disorder	occurred	in	the	context	of	multiple	gallstones.	Most	Grade	
3	elevations	in	total	bilirubin	occurred	in	patients	with	pre‐existing	
elevations	 (Grade	 1	 or	 2)	 and	 were	 transient	 in	 nature,	 resulting	
predominantly	from	increased	 indirect	bilirubin	fraction	consistent	
with	known	glecaprevir	effects	on	bilirubin	transport	(inhibition	of	
OATP1B1)	and	conjugation.18
3.5 | Exploratory analysis of patient‐
reported outcomes
Mean	change	(±SD)	in	PROs	related	to	neuropsychiatric	function	was	
evaluated	to	assess	QoL	changes	in	patients	with	and	without	psychiat‐
ric	disorders	using	the	SF‐36	MCS	and	FSS	from	8	of	the	10	clinical	tri‐
als	(SURVEYOR‐I	and	SURVEYOR‐II,	ENDURANCE‐2,	ENDURANCE‐3	
and	 ENDURANCE‐4,	 and	 EXPEDITION‐1,	 EXPEDITION‐2	 and	
EXPEDITION‐4).	With	available	data	from	the	SF‐36	MCS	for	538	pa‐
tients	with	a	psychiatric	disorder	and	1077	patients	without	a	psychi‐
atric	disorder,	 there	was	a	trend	towards	 increased	mental	health	at	
Event, n (%)
Patients with psychiatric 
disorder 
N = 789
Patients without a psychiatric 
disorder 
N = 1733
Any	AE 610	(77) 1087	(63)
Any	neuropsychiatric	
AEa
64	(8) 52	(3)
Serious	AE 30	(4) 47	(3)
DAA‐related	serious	
AE
0 1	(<1)b
AEs	leading	to	
discontinuation
5	(<1) 8	(<1)
DAA‐related	AEs	lead‐
ing	to	discontinuation
2	(<1)c 3	(<1)d
AEs	occurring	in	≥10%	of	patients
Headache 158	(20) 273	(16)
Fatigue 140	(18) 223	(13)
Nausea 102	(13) 131	(8)
Laboratory	Abnormalities
ALT,	grade	≥3e 1	(<1) 1	(<1)
AST,	grade	≥3 3	(<1) 3	(<1)
Total	bilirubin,	grade	
≥3
6	(<1) 4	(<1)
Abbreviations:	AE,	adverse	event;	ALT,	alanine	aminotransferase;	AST,	aspartate	aminotransferase;	
DAA,	direct‐acting	antiviral.
aAny	AE	included	under	standardized	MedDRA	queries	of	depression,	suicide/self‐injury	and	
psychosis.	
bGrade	3	transient	ischaemic	attacks	on	Day	11	in	patient	with	history	of	smoking,	obesity	and	a	
cardiac	conduction	abnormality	along	with	elevated	haemoglobin	and	haematocrit	at	screening.	
This	patient	subsequently	experienced	another	SAE	of	transient	ischaemic	attack	on	Day	36	(24	d	
after	discontinuing	G/P	treatment).	
cTwo	patients	experienced	8	nonserious	AEs	leading	to	treatment	discontinuation	(dyspepsia,	
nausea,	diarrhoea,	dizziness,	fatigue,	malaise,	abdominal	pain	and	headache).	
dOne	patient	experienced	a	nonserious	AE	of	diarrhoea	on	Day	27;	two	other	patients	with	pre‐
existing	conditions	experienced	serious	AEs	of	transient	ischaemic	attack	on	Day	11	and	pruritus	
on Day 61. 
ePost‐nadir	increase	(in	grade).	
TA B L E  4  Adverse	events	and	
laboratory	abnormalities
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post‐treatment	week	12.	A	numerically	higher	increase	was	observed	
in	patients	with	a	psychiatric	disorder	(3.6	±	11.7)	compared	to	those	
without	a	psychiatric	disorder	(2.2	±	9.6).	Likewise,	available	data	from	
542	and	1080	patients	with	and	without	psychiatric	disorders,	respec‐
tively,	 showed	 a	 trend	 at	 post‐treatment	 week	 12	 towards	 slightly	
decreased	fatigue	scores	as	assessed	by	the	FSS	in	patients	with	and	
without	psychiatric	disorders	(−0.5	±	1.6	and	−0.3	±	1.6,	respectively).
4  | DISCUSSION
The	 pangenotypic,	 once‐daily	DAA	 regimen	 of	G/P	 achieved	 high	
(>97%)	SVR12	rates	in	both	patients	with	and	without	a	psychiatric	
disorder.	In	patients	with	a	psychiatric	disorder,	G/P	achieved	>96%	
SVR12	rates	regardless	of	psychiatric	diagnoses	or	the	prescription	
of	neuropsychiatric	co‐medications,	in	spite	of	a	numerically	higher	
prevalence	of	GT3	 infection	 in	 patients	with	 psychiatric	 disorders	
likely	due	to	the	higher	prevalence	of	GT3	infection	among	patients	
with	a	history	of	substance	use.29,30	Overall,	 treatment	adherence	
was	>95%	for	both	patients	with	or	without	psychiatric	disorders.	
G/P	was	well	tolerated	in	both	patients	with	and	without	psychiat‐
ric	disorders,	exhibiting	similarly	 low	rates	of	serious	AEs	and	AEs	
leading	to	G/P	discontinuation.	Patients	with	psychiatric	disorders	
treated	with	G/P	did	not	have	higher	rates	of	lost	to	follow‐up	or	pre‐
mature	discontinuations	resulting	in	non‐SVR	compared	to	patients	
without	psychiatric	disorders.	An	exploratory	analysis	of	PROs	re‐
lated	to	neuropsychiatric	function	demonstrated	trends	towards	im‐
provements	in	mental	health	and	fatigue	especially	in	patients	with	
psychiatric	disorders.	Overall,	G/P	is	highly	efficacious	and	safe	with	
high	adherence	rates	in	this	large	clinical	trial	cohort	of	patients	with	
psychiatric	disorders.	Our	findings	are	consistent	with	those	of	other	
DAA	regimens	in	clinical	trial	populations.31,32
Adherence	among	patients	with	chronic	HCV	infection	and	co‐
morbid	psychiatric	disorders	remains	a	concern	despite	the	advent	
of	IFN‐free	DAA	treatments.	Lower	adherence	is	hypothesized	due	
to	cases	of	severe,	untreated	psychiatric	disorders	and	higher	rates	
of	comorbid	substance	use	disorders	3,11‐13;	however,	DAA	regimens	
have	 shown	 similarly	 high	 adherence	 rates	 in	 clinical	 trials	 among	
patient	populations	traditionally	considered	to	be	at‐risk	for	nonad‐
herence	 including	 patients	with	 psychiatric	 disorders,	 people	who	
inject	drugs	and	patients	on	stable	opioid	substitution	therapy.29,31 
In	its	clinical	trial	programme,	overall	adherence	to	G/P	regimens	has	
been	reported	at	>95%	with	comparable	rates	among	patients	with	
psychiatric	disorders,	people	who	inject	drugs	and	patients	on	sta‐
ble	opioid	substitution	therapy.33,34	Although	treatment	adherence	
was	almost	90%	in	patients	with	bipolar	disorder,	nonadherence	to	
medication	was	more	common	among	patients	with	bipolar	disorder	
in	line	with	previous	studies.35	However,	it	is	conceivable	that	real‐
world	 cohorts	 with	 more	 severe,	 untreated	 psychiatric	 disorders	
may	be	at‐risk	for	lower	treatment	adherence	with	DAAs	including	
G/P.	Shorter	treatment	regimens	with	G/P	may	facilitate	improved	
adherence	in	clinical	practice	since	other	DAA	regimens	have	shown	
decreased	 adherence	 over	 12‐week	 treatment.36	 Additionally,	 as	
evidenced	by	the	 low	rate	of	virologic	failure	using	a	modified	ITT	
analysis,	 G/P	 provides	 a	 durable	 treatment	 regimen	with	 similarly	
high	efficacy	in	patients	who	are	nonadherent	(<80%)	compared	to	
those	who	are	adherent.37
In	 the	 era	 of	 IFN‐free	 DAAs,	 concerns	 over	 DDIs,	 not	 safety,	
are	 relevant	 to	 treatment	 decisions	 for	 patients	 with	 psychiatric	
disorders.	 Similar	 to	 other	 DAAs,	 these	 data	 generated	 with	 G/P	
regimens	further	support	the	consistent	finding	that	DAAs	are	well‐
tolerated	and	are	not	associated	with	 increased	psychiatric	AEs	as	
seen	with	IFN‐based	treatments.3,31,38,39	Although	treatment‐emer‐
gent	 psychiatric	 AEs	 are	 not	 a	 concern	with	DAAs,	 current	 treat‐
ment	guidelines	recommend	assessment	for	potential	DDIs	prior	to	
HCV	treatment	initiation.9,10	This	is	particularly	relevant	for	patients	
taking	neuropsychiatric	medications	since	all	available	DAAs,	includ‐
ing	 G/P,	 are	 contraindicated	 with	 carbamazepine	 and	 most	 other	
anticonvulsants	due	 to	known	DDIs.18,40‐43	Among	other	common	
co‐medications	including	drugs	for	neuropsychiatric	disorders,	G/P	
demonstrated	limited	potential	DDIs;	however,	its	activity	as	a	weak	
CYP3A4	 inhibitor	 could	potentiate	DDIs	with	 the	common	neuro‐
psychiatric	 co‐medications,	 quetiapine,	 hydrocodone	 and	 oxyco‐
done.18	Overall,	G/P	was	safe	and	efficacious	in	patients	taking	any	
of	these	neuropsychiatric	co‐medications	with	potential	DDIs.
Neuropsychiatric	 manifestations	 of	 HCV	 are	 commonly	 re‐
ported,	 and	 their	 severity	 can	be	 alleviated	with	 the	 achievement	
of	SVR.1	In	G/P's	clinical	trials	programme	reported	here,	the	trends	
towards	 improvements	 in	 PROs	 related	 to	 neuropsychiatric	 func‐
tion	mirror	those	improvements	reported	with	other	DAA	regimens,	
particularly	the	numerically	larger	effect	in	patients	with	psychiatric	
disorders;	thus,	these	findings	warrant	further	investigation.4,39,44‐49 
Further	long‐term	follow‐up	may	be	necessary	in	order	to	observe	
whether	these	trends	are	both	robust	and	durable	over	time.
There	are	limitations	to	this	analysis	that	are	inherent	to	its	de‐
sign.	Since	this	is	a	post	hoc	analysis,	the	comparisons	between	pa‐
tients	with	and	without	a	psychiatric	disorder	were	not	pre‐specified	
and,	thus,	are	not	powered	to	assess	for	differences	between	these	
patient	populations.	 It	 is	 not	 valid	 to	 compare	psychiatric	AEs	be‐
tween	patients	with	or	without	a	psychiatric	disorder	as	 there	are	
most	likely	to	be	different	risk	factors	or	comorbidities	for	each	of	
these	groups	contributing	 to	 their	psychiatric	AEs.	The	 ideal	 anal‐
ysis	would	 involve	a	direct	comparison	of	patients	 treated	with	or	
without	 G/P	 with	 psychiatric	 disorders.	 Additionally,	 the	 patients	
with	 psychiatric	 disorders	 enrolled	 in	 clinical	 trials	 are	 a	more	 se‐
lected	 population	 potentially	 with	 more	 controlled	 disorders	 and	
an	 underrepresentation	 of	 Black	 or	 African‐Americans	 compared	
to	 patients	 in	 the	 real‐world	 setting;	 therefore,	 it	 is	 important	 to	
validate	 these	 findings	with	data	obtained	 from	 real‐world	 clinical	
practice.	Of	note,	30%	of	patients	with	psychiatric	disorders	were	
treatment‐experienced	 with	 most	 receiving	 interferon‐containing	
regimens,	suggesting	that	these	patients	had	less	severe	psychiatric	
disorders	since	interferon	is	contraindicated	for	patients	with	severe	
psychiatric	disorders.	Additionally,	77	patients	were	excluded	from	
these	studies	as	a	result	of	a	clinically	significant	abnormality	other	
than	HCV	infection	due	to	a	cluster	of	clinical	abnormalities	of	which	
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may	or	may	not	have	included	an	uncontrolled	psychiatric	disorder.	
Full	 details	 are	 listed	 in	 the	 Supporting	 Information.	 Finally,	 treat‐
ment	adherence	was	assessed	 in	 these	clinical	 trials	by	measuring	
pill	counts	that	provide	quantitative	data	on	adherence	at	specified	
visits,	but	can	overestimate	overall	adherence	and	lacks	any	informa‐
tion	on	dose	timing.50
Overall,	among	the	789	(31%)	patients	with	a	psychiatric	disorder	
in	its	clinical	trials	programme,	G/P	demonstrated	comparably	high	
SVR12	rates	and	treatment	adherence	to	those	observed	in	patients	
without	a	psychiatric	disorder.	Despite	a	higher	rate	of	mild‐to‐mod‐
erate	AEs	 in	patients	with	psychiatric	disorders,	G/P	was	well	 tol‐
erated	with	similarly	low	rates	of	serious	AEs	or	AEs	leading	to	G/P	
discontinuation	 in	 patients	 with	 or	 without	 psychiatric	 disorders.	
Thus,	G/P	 is	a	pangenotypic	regimen	suitable	for	treatment	of	the	
≤50%	of	patients	with	chronic	HCV	infection	and	comorbid	psychi‐
atric	disorders.
ACKNOWLEDG EMENT
Medical	writing	support	was	provided	by	Daniel	O'Brien,	Ph.D.,	of	
AbbVie.
CONFLIC T OF INTERE S TS
David	Back:	Advisory	board	member/speakers	bureau	and	receives	
honorarium	 from:	 Gilead,	 Merck,	 AbbVie,	 Bristol‐Myers	 Squibb,	
Janssen;	received	research	grant	funding	from:	Gilead,	Merck,	AbbVie,	
Bristol‐Myers	 Squibb,	 Janssen;	 received	 travel	 sponsorship	 from:	
AbbVie.	Pamela	Belperio:	Nothing	to	disclose.	Fiona	Marra:	consult‐
ing	or	grants	from	AbbVie,	Gilead,	Merck,	Janssen	and	Viiv.	Francesco	
Negro:	 advisor	 to	 Gilead,	 AbbVie,	 Merck.	 Unrestricted	 research	
grant	from	AbbVie.	Investigator	initiated	study	supported	by	Gilead.	
Andrew	 Talal:	 Research	 grants:	 AbbVie,	 Merck,	 Gilead,	 Intercept,	
Conatus,	Abbott,	Genfit,	Center	for	AIDS	Research,	Patient‐Centered	
Outcomes	 Research	 Institute	 (PCORI);	 Advisor:	 AbbVie,	 Merck,	
Abbott	 Diagnostics,	 Chronic	 Liver	 Disease	 Foundation;	 Speaker's	
Bureau:	 Chronic	 Liver	 Disease	 Foundation.	Mark	 Bondin,	 Caroline	
Park,	ZhenZhen	Zhang,	Brett	Pinsky,	Federico	Mensa,	Eric	Crown	are	
employees	of	AbbVie,	Inc	and	may	hold	stock	or	stock	options.
ORCID
Pamela Belperio  https://orcid.org/0000‐0002‐6435‐7450 
Andrew H. Talal  https://orcid.org/0000‐0002‐5565‐7515 
R E FE R E N C E S
	 1.	 Adinolfi	LE,	Nevola	R,	Lus	G,	et	al.	Chronic	hepatitis	C	virus	infec‐
tion	and	neurological	and	psychiatric	disorders:	an	overview.	World 
J Gastroenterol.	2015;21(8):2269‐2280.
	 2.	 Rifai	MA,	Gleason	OC,	Sabouni	D.	Psychiatric	care	of	 the	patient	
with	hepatitis	C:	a	review	of	the	literature.	Primary Care Companion 
to The Journal of Clinical Psychiatry.	2010;12(6):PCC.09r00877.
	 3.	 Hauser	P,	Kern	S.	Psychiatric	and	substance	use	disorders	co‐mor‐
bidities	 and	 hepatitis	 C:	 diagnostic	 and	 treatment	 implications.	
World J Hepatol.	2015;7(15):1921‐1935.
	 4.	 Younossi	Z,	Henry	L.	Systematic	review:	patient‐reported	outcomes	
in	 chronic	 hepatitis	 C–the	 impact	 of	 liver	 disease	 and	 new	 treat‐
ment	regimens.	Aliment Pharmacol Ther.	2015;41(6):497‐520.
	 5.	 Marcellin	 F,	 Roux	 P,	 Protopopescu	 C,	 Duracinsky	 M,	 Spire	 B,	
Carrieri	 MP.	 Patient‐reported	 outcomes	 with	 direct‐acting	 an‐
tivirals	 for	 the	 treatment	 of	 chronic	 hepatitis	 C:	 current	 knowl‐
edge	 and	 outstanding	 issues.	 Expert Rev Gastroenterol Hepatol. 
2017;11(3):259‐268.
	 6.	 Soriano	V,	Fernandez‐Montero	JV,	de	Mendoza	C,	et	al.	Treatment	
of	 hepatitis	 C	 with	 new	 fixed	 dose	 combinations.	 Expert Opin 
Pharmacother.	2017;18(12):1235‐1242.
	 7.	 Vermehren	J,	Park	JS,	 Jacobson	 I,	Zeuzem	S.	Challenges	and	per‐
spectives	of	direct	antivirals	for	the	treatment	of	hepatitis	C	virus	
infection.	J Hepatol.	2018;69:1178‐1187.
	 8.	 Hezode	 C.	 Treatment	 of	 hepatitis	 C:	 results	 in	 real	 life.	 Liver Int. 
2018;38(Suppl	1):21‐27.
	 9.	 AASLD.	HCV	Guidance:	Recommendations	for	Testing,	Managing,	
and	Treating	Hepatitis	C.	2017.
	10.	 EASL.	European	association	for	the	study	of	the	liver	recommenda‐
tions	on	treatment	of	hepatitis	C	2018.	J Hepatol. 2018;69:461–511.
	11.	 Ford	MM,	 Johnson	N,	Desai	 P,	 Rude	 E,	 Laraque	 F.	 From	 care	 to	
cure:	demonstrating	a	model	of	clinical	patient	navigation	for	hep‐
atitis	 C	 care	 and	 treatment	 in	 high‐need	 patients.	Clin Infect Dis. 
2017;64(5):685–691.
	12.	 Lin	M,	Kramer	J,	White	D,	et	al.	Barriers	to	hepatitis	C	treatment	
in	the	era	of	direct‐acting	anti‐viral	agents.	Aliment Pharmacol Ther. 
2017;46(10):992–1000.
	13.	 Langness	 JA,	 Nguyen	 M,	 Wieland	 A,	 Everson	 GT,	 Kiser	 JJ.	
Optimizing	 hepatitis	 C	 virus	 treatment	 through	 pharmacist	 inter‐
ventions:	Identification	and	management	of	drug‐drug	interactions.	
World J Gastroenterol.	2017;23(9):1618–1626.
	14.	 Jain	MK,	Thamer	M,	Therapondos	G,	et	al.	Has	access	to	HCV	ther‐
apy	changed	for	patients	with	mental	health	or	substance	use	dis‐
orders	in	the	DAA	period?	Hepatology.	2018;69:51‐63.
	15.	 Ng	TI,	Krishnan	P,	Pilot‐Matias	T,	et	al.	In	vitro	antiviral	activity	and	
resistance	profile	of	the	next‐generation	hepatitis	C	virus	NS5A	in‐
hibitor	pibrentasvir.	Antimicrob Agents Chemother.	2017;61(5):e025
58–e2616.
	16.	 Ng	TI,	Tripathi	R,	Reisch	T,	et	al.	In	vitro	antiviral	activity	and	resis‐
tance	profile	of	the	next‐generation	hepatitis	C	virus	NS3/4A	prote‐
ase	inhibitor	glecaprevir.	Antimicrob Agents Chemother.	2017;62(1):	
e01620‐17.
	17.	 European	 Public	 Assessment	 Report	 (EPAR):	 glecaprevir	 and	 pi‐
brentasvir.	2017.
	18.	 MAVYRET	(glecaprevir	and	pibrentasvir)	[package	insert].	AbbVie.	
North	Chicago,	IL.
	19.	 Poordad	F,	Felizarta	F,	Asatryan	A,	et	al.	Glecaprevir	and	pibrentas‐
vir	for	12	weeks	for	hepatitis	C	virus	genotype	1	infection	and	prior	
direct‐acting	antiviral	treatment.	Hepatology.	2017;66(2):389–397.
	20.	 Poordad	F,	Pol	S,	Asatryan	A,	et	al.	Glecaprevir/Pibrentasvir	in	pa‐
tients	with	HCV	genotype	1	or	4	and	prior	direct‐acting	antiviral	
treatment	failure.	Hepatology.	2018;67(4):1253–1260.
	21.	 Kwo	PY,	Poordad	F,	Asatryan	A,	et	al.	Glecaprevir	and	pibrentasvir	
yield	high	response	rates	in	patients	with	HCV	genotype	1–6	with‐
out	cirrhosis.	J Hepatol.	2017;67(2):263–271.
	22.	 Zeuzem	S,	 Foster	GR,	Wang	S,	 et	 al.	Glecaprevir‐pibrentasvir	 for	
8	 or	 12	weeks	 in	 HCV	 genotype	 1	 or	 3	 infection.	N Engl J Med. 
2018;378(4):354–369.
	23.	 Asselah	T,	Kowdley	KV,	Zadeikis	N,	et	al.	Efficacy	of	glecaprevir/
pibrentasvir	 for	 8	 or	 12	weeks	 in	 patients	with	 hepatitis	 C	 virus	
genotype	2,	4,	5,	or	6	infection	without	cirrhosis.	Clin Gastroenterol 
Hepatol.	2018;16(3):417–426.
960  |     BACK et Al.
	24.	 Forns	 X,	 Lee	 SS,	 Valdes	 J,	 et	 al.	 Glecaprevir	 plus	 pibrentas‐
vir	 for	 chronic	 hepatitis	 C	 virus	 genotype	 1,	 2,	 4,	 5,	 or	 6	 infec‐
tion	 in	 adults	 with	 compensated	 cirrhosis	 (EXPEDITION‐1):	 a	
single‐arm,	open‐label,	multicentre	phase	3	trial.	Lancet Infect Dis. 
2017;17(10):1062–1068.
	25.	 Gane	 E,	 Lawitz	 E,	 Pugatch	D,	 et	 al.	 Glecaprevir	 and	 pibrentasvir	
in	patients	with	HCV	and	 severe	 renal	 impairment.	N Engl J Med. 
2017;377(15):1448–1455.
	26.	 Rockstroh	JK,	Lacombe	K,	Trinh	R,	et	al.	Efficacy	and	safety	of	gle‐
caprevir/pibrentasvir	in	patients	co‐infected	with	hepatitis	C	virus	
and	 human	 immunodeficiency	 virus‐1:	 the	 EXPEDITION‐2	 study.	
Clin Infect Dis.	2018;67(7):1010–1017.
	27.	 Cornberg	 M,	 Naumann	 U,	 Stoehr	 A,	 et	 al.	 Real‐world	 data	 on	
safety	and	effectiveness	of	glecaprevir/pibrentasvir	 for	 the	treat‐
ment	of	patients	with	chronic	hepatitis	C	virus	 infection:	updated	
data	 from	 the	 German	 Hepatitis	 C‐Registry.	 J Viral Hepatitis. 
2018;25(S2):197–198.
	28.	 D’Ambrosio	R,	Pasulo	L,	Puoti	M,	et	al.	Real‐life	effectiveness	and	
safety	of	Glecaprevir/Pibrentasvir	among	723	Italian	patients	with	
chronic	hepatitis	C:	the	navigator‐II	study.	J Hepatol. 2018;68:S65.
	29.	 Grebely	 J,	 Hajarizadeh	 B,	Dore	GJ.	Direct‐acting	 antiviral	 agents	
for	 HCV	 infection	 affecting	 people	 who	 inject	 drugs.	 Nat Rev 
Gastroenterol Hepatol.	2017;14(11):641–651.
	30.	 Flamm	 S,	Mutimer	D,	 Asatryan	 A,	 et	 al.	 Glecaprevir/Pibrentasvir	
in	patients	with	chronic	HCV	genotype	3	 infection:	an	 integrated	
phase	2/3	analysis.	J Viral Hepat. 2018.
	31.	 Tang	L,	Masur	J,	Sims	Z,	et	al.	Safe	and	effective	sofosbuvir‐based	
therapy	in	patients	with	mental	health	disease	on	hepatitis	C	virus	
treatment. World J Hepatol.	2016;8(31):1318–1326.
	32.	 Perumalswami	PV,	Talal	AH.	Improvements	in	quality	of	life:	a	new	
indication	 for	 treating	 hepatitis	 C	 virus	 infection	 in	 persons	with	
substance	use	disorders.	J Infect Dis.	2018;217(7):1020–1023.
	33.	 Grebely	 J,	 Dore	 GJ,	 Alami	 NN,	 et	 al.	 Safety	 and	 Efficacy	 of	
Glecaprevir/Pibrentasvir	in	Patients	with	Chronic	HCV	Genotypes	
1‐6	Receiving	Opioid	Substitution	Therapy.	International	Network	
on	Hepatitis	in	Substance	Users	(INHSU)	New	York,	NY,	2017.
	34.	 Foster	 GR,	 Grebely	 J,	 Sherman	 KE,	 et	 al.	 Safety	 and	 efficacy	 of	
Glecaprevir/Pibrentasvir	in	patients	with	chronic	hepatitis	C	geno‐
types	1–6	and	recent	drug	use.	Hepatology.	2017;66(S1):636–637.
	35.	 Jawad	I,	Watson	S,	Haddad	PM,	Talbot	PS,	McAllister‐Williams	RH.	
Medication	nonadherence	 in	 bipolar	 disorder:	 a	 narrative	 review.	
Ther Adv Psychopharmacol.	2018;8(12):349–363.
	36.	 Townsend	K,	Petersen	T,	Gordon	LA,	et	al.	Effect	of	HIV	co‐infec‐
tion	on	adherence	to	a	12‐week	regimen	of	hepatitis	C	virus	therapy	
with	ledipasvir	and	sofosbuvir.	AIDS.	2016;30(2):261–266.
	37.	 Brown	AS,	Welzel	TM,	Conway	B,	et	al.	Adherence	to	pangenotypic	
Glecaprevir/Pibrentasvir	treatment	and	SVR12	in	HCV‐infected	pa‐
tients:	an	integrated	analysis	of	the	phase	2/3	clinical	trial	program.	
J Hepatol.	2017;66(S1):114A–A115.
	38.	 Banerjee	D,	Reddy	KR.	Review	article:	safety	and	tolerability	of	di‐
rect‐acting	anti‐viral	agents	in	the	new	era	of	hepatitis	C	therapy.	
Aliment Pharmacol Ther.	2016;43(6):674–696.
	39.	 Dore	GJ,	Conway	B,	Luo	Y,	et	al.	Efficacy	and	safety	of	ombitasvir/
paritaprevir/r	and	dasabuvir	compared	to	IFN‐containing	regimens	
in	genotype	1	HCV	patients:	The	MALACHITE‐I/II	trials.	J Hepatol. 
2016;64(1):19–28.
	40.	 ZEPETIER	(elbasvir	and	grazoprevir)	[package	insert].	Merck	&	Co.,	
Whitehouse	Station,	NJ.
	41.	 EPCLUSA	 (sofosbuvir	 and	 velpatasvir)	 [package	 insert].	 Gilead	
Sciences,	Inc.,	Foster	City,	CA.
	42.	 HARVONI	 (ledipasvir	 and	 sofosbuvir)	 [package	 insert].	 Gilead	
Sciences,	Inc.,	Foster	City,	CA.
	43.	 VIEKIRA	 XR	 (dasabuvir,	 ombitasvir,	 paritaprevir,	 and	 ritonavir)
[package	insert].	AbbVie.	North	Chicago,	IL.
	44.	 Younossi	ZM,	Stepanova	M,	Charlton	M,	et	al.	Patient‐reported	out‐
comes	with	sofosbuvir	and	velpatasvir	with	or	without	ribavirin	for	
hepatitis	C	virus‐related	decompensated	cirrhosis:	an	exploratory	
analysis	from	the	randomised,	open‐label	ASTRAL‐4	phase	3	trial.	
Lancet Gastroenterol Hepatol.	2016;1(2):122–132.
	45.	 Younossi	ZM,	Stepanova	M,	Feld	J,	et	al.	Sofosbuvir/velpatasvir	im‐
proves	 patient‐reported	outcomes	 in	HCV	patients:	 Results	 from	
ASTRAL‐1	placebo‐controlled	trial.	J Hepatol.	2016;65(1):33–39.
	46.	 Younossi	ZM,	Stepanova	M,	Sulkowski	M,	et	al.	Ribavirin‐free	regi‐
men	with	sofosbuvir	and	velpatasvir	is	associated	with	high	efficacy	
and	 improvement	 of	 patient‐reported	 outcomes	 in	 patients	 with	
genotypes	2	and	3	chronic	hepatitis	c:	results	from	astral‐2	and	‐3	
clinical	trials.	Clin Infect Dis.	2016;63(8):1042–1048.
	47.	 Younossi	ZM,	Stepanova	M,	Sulkowski	M,	Naggie	S,	Henry	L,	Hunt	
S.	Sofosbuvir	and	ledipasvir	improve	patient‐reported	outcomes	in	
patients	co‐infected	with	hepatitis	C	and	human	immunodeficiency	
virus.	J Viral Hepat.	2016;23(11):857–865.
	48.	 Younossi	 ZM,	 Stepanova	 M,	 Sulkowski	 M,	 Wyles	 D,	 Kottilil	 S,	
Hunt	 S.	 Patient‐reported	 outcomes	 in	 patients	 co‐infected	 with	
hepatitis	 C	 virus	 and	 human	 immunodeficiency	 virus	 treated	
with	 sofosbuvir	 and	 velpatasvir:	 The	 ASTRAL‐5	 study.	 Liver Int. 
2017;37(12):1796–1804.
	49.	 Stepanova	M,	Thompson	A,	Doyle	J,	Younossi	I,	de	Avila	L,	Younossi	
ZM.	Hepatitis	C	virus‐infected	patients	 receiving	opioid	 substitu‐
tion	 therapy	 experience	 improvement	 in	 patient‐reported	 out‐
comes	following	treatment	with	 interferon‐free	regimens.	J Infect 
Dis.	2018;217(7):1033–1043.
	50.	 Osterberg	L,	Blaschke	T.	Adherence	 to	medication.	N Engl J Med. 
2005;353:487–497.
SUPPORTING INFORMATION
Additional	 supporting	 information	 may	 be	 found	 online	 in	 the	
Supporting	Information	section	at	the	end	of	the	article.	
How to cite this article:	Back	D,	Belperio	P,	Bondin	M,	et	al.	
Efficacy	and	safety	of	glecaprevir/pibrentasvir	in	patients	with	
chronic	HCV	infection	and	psychiatric	disorders:	An	integrated	
analysis.	J Viral Hepat. 2019;26:951–960. https	://doi.
org/10.1111/jvh.13110	
